pembrolizumab
merck
['keynote,54', 'pembro']
new data from #esmo22 in a new, long-term qol analysis of keynote-054, a phase iii trial, adjuvant pembrolizumab and placebo were found to have no clinically relevant differences in long-term global qol and physical functioning. 